[2] Jones DR.A potential osteoporosis target in the FAS ligand/FAS pathway of osteoblast to osteoclast signaling. Ann Transl Med.2015;3(14):189.
[3] 王袖和,王长庆,朱玉平,等.雌激素干预骨质疏松大鼠牙槽骨改建过程中白细胞介素1的表达.中国组织工程研究, 2013,17(46):8012-8017.
[4] Okazaki R.Pharmacological treatment of other types of secondary osteoporosis.Nihon Rinsho.2015;73(10): 1740-1745.
[5] 卢守亮.绝经后骨质疏松症妇女血清Il-8、10水平及雌激素对去势大鼠血清Il-8、10水平影响[D].天津医科大学, 2013.
[6] Ostrowska Z,Ziora K,O?wi?cimska J,et al.Selected pro-inflammatory cytokines, bone metabolism, osteoprotegerin, and receptor activator of nuclear factor-kB ligand in girls with anorexia nervosa. Endokrynol Pol.2015;66(4):313-21.
[7] Al-Daghri NM,Yakout S,Al-Shehri E,et al.Inflammatory and bone turnover markers in relation to PTH and vitamin D status among saudi postmenopausal women with and without osteoporosis.Int J Clin Exp Med.2014; 7(10):3528-3535.
[8] He LH,Xiao E,Duan DH,et al.Osteoclast Deficiency Contributes to Temporomandibular Joint Ankylosed Bone Mass Formation.J Dent Res.2015;94(10): 1392-1400.
[9] 毛海琴,杜义斌,徐莹,等.骨疏颗粒对去卵巢骨质疏松大鼠骨密度及血清细胞因子的影响[J].环球中医药,2015,(9): 1081-1084.
[10] Ardawi MM,Badawoud MH,Hassan SM,et al.Lycopene treatment against loss of bone mass, microarchitecture and strength in relation to regulatory mechanisms in a postmenopausal osteoporosis model.Bone.2015;83: 127-140.
[11] Taylan A,Sari I,Akinci B,et al.Biomarkers and cytokines of bone turnover: extensive evaluation in a cohort of patients with ankylosing spondylitis.BMC Musculoskelet Disord.2012;13:191.
[12] 邵泓达,汤光宇.去势骨质疏松的发病机制研究进展[J].上海医学,2014,37(1):94-96.
[13] 张国如,陈柏龄,吴兴源,等.细胞因子在大鼠骨质疏松及疼痛中作用机制[J].中华实用诊断与治疗杂志,2015,29(2): 162-163.
[14] Pineda B,Hermenegildo C,Tarín JJ,et al.Effects of administration of hormone therapy or raloxifene on the immune system and on biochemical markers of bone remodeling.Menopause.2012;19(3):319-327.
[15] Qian H,Yuan H,Wang J,et al.A monoclonal antibody ameliorates local inflammation and osteoporosis by targeting TNF-α and RANKL.Int Immunopharmacol. 2014;20(2):370-376.
[16] Rahnama M,Jastrz?bska I,Jamrogiewicz R,et al.IL-1α and IL-1β levels in blood serum and saliva of menopausal women.Endocr Res. 2013;38(2):69-76.
[17] 吴迎爽.吡格列酮对去卵巢大鼠IL-1β、IL-6、TNF-a的影响及与骨代谢关系的实验研究[D].山西医科大学, 2012.
[18] Mozzati M,Martinasso G,Maggiora M,et al.Oral mucosa produces cytokines and factors influencing osteoclast activity and endothelial cell proliferation, in patients with osteonecrosis of jaw after treatment with zoledronic acid.Clin Oral Investig.2013;17(4): 1259-1266.
[19] Vijayan V,Khandelwal M,Manglani K,et al. Homocysteine alters the osteoprotegerin/RANKL system in the osteoblast to promote bone loss: pivotal role of the redox regulator forkhead O1.Free Radic Biol Med.2013;61:72-84.
[20] Martínez-Calatrava MJ,Prieto-Potín I,Roman-Blas JA,et al.RANKL synthesized by articular chondrocytes contributes to juxta-articular bone loss in chronic arthritis. Arthritis Res Ther.2012;14(3):R149.
[21] Yu H,Herbert BA,Valerio M,et al.FTY720 inhibited proinflammatory cytokine release and osteoclastogenesis induced by Aggregatibacter actinomycetemcomitans.Lipids Health Dis.2015;14:66.
[22] Thongchote K,Svasti S,Teerapornpuntakit J,et al.Running exercise alleviates trabecular bone loss and osteopenia in hemizygous β-globin knockout thalassemic mice.Am J Physiol Endocrinol Metab. 2014;306(12):E1406-17.
[23] Wang Y,Yang C,Xie WL,et al.Puerarin concurrently stimulates osteoprotegerin and inhibits receptor activator of NF-κB ligand (RANKL) and interleukin-6 production in human osteoblastic MG-63 cells. Phytomedicine.2014;21(8-9):1032-1036.
[24] Chipoy C,Brounais B,Trichet V,et al.Sensitization of osteosarcoma cells to apoptosis by oncostatin M depends on STAT5 and p53.Oncogene.2007;26(46): 6653-6664.